ERBB4 and colorectal carcinoma: In Mondaca-CRC, the HR-MUT group was notably higher than the HR-WT group in RNF43 (17.3% vs. 6.2%), ARID1A (21.0% vs. 4.9%), KMT2D (22.2% vs. 4.7%), PTPRS (18.5% vs. 4.7%), ERBB4 (12.3% vs. 4.1%), PTPRT (11.1% vs. 4.1%), NF1 (9.9% vs. 4.1%), and PTEN (11.1% vs. 3.6%), all of which had significantly increased mutation frequency (all p < 0.05; Figure 4B).